Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of Aptinyx (NASD: APTX), Areteia Therapeutics, Cardurion Pharmaceuticals, Cerevel Therapeutics (NASD: CERE), Foghorn Therapeutics (NASD: FHTX) and Solid Biosciences (NASD: SLDB).

Dr. Koppel has also previously served on the Board of Directors for Dicerna Pharmaceuticals (NASD: DRNA), Trevena, Inc (NASD: TRVN) and PTC Therapeutics (NASD: PTCT).

Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies.

Dr. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Boston Museum of Science Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. In addition, he sits on the Gann Academy Board of Trustees and CJP’s Budget and Administration Committee. He previously sat on the Board of Temple Beth Elohim in Wellesley MA, from 2014-2017.

Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.